Listed cannabis firm Bod Australia has claimed its third biggest sales month on record, with prescriptions for its MediCabilis product in April rising 35% on the previous month.

Prescriptions climbed from 382 to 516, the company said in a statement on the ASX. Six out of 10 prescriptions were repeats.

Bod Australia said it was on course to exceed the 1,099 prescriptions written in the third quarter.

The April increase took the total number of MediCabilis prescriptions since last July to 3,459.

The company said sales for the remainder of the year are likely to be bolstered by its first batch of prescriptions from UK patients as part of the Europe-based Project Twenty21.

Jo Patterson - Medical Cannabis Australia - Cannabiz
Bod CEO Jo Patterson “pleased with steady sales increase”

The project hopes to enrol 20,000 people by the end of 2021 with the aim of “creating the largest body of evidence for the effectiveness and tolerability of medicinal cannabis”.

The organisation behind the initiative, Drug Science, described it as a registry rather than a clinical trial,

Bod chief executive Jo Patterson said the company was pleased with the “steady increase” in sales”.

“Achieving 516 MediCabilis prescriptions and a strong repeat purchase rate in April is a great result for Bod,” she said.

“Following our recent market entry into the United Kingdom and through our participation in Project Twenty21, we anticipate that prescription volumes will continue to rise.”

Shares in Bod climbed 1.6% to 0.32c.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...